There is a wonderfully inconvenient truth hiding below the stock market's celebrity layer. The television cameras can spend all day swiveling between Nvidia, Apple and Tesla, but American exchanges contain thousands of other public companies. Many are too small to matter to a giant fund. A billion-dollar manager cannot build a meaningful position without moving the price, and a bank cannot justify assigning an analyst to every obscure midcap. Behind the Markets has built an entire publishing company inside that institutional shrug.
Founded in 2018 and based in Boca Raton, Florida, the firm sells independent investment research to individual investors. Founder and CEO Dylan Jovine is the face, voice and organizing argument. His pitch is not that Wall Street lacks intelligence. It is that Wall Street's economics produce blind spots. A retail investor with a modest portfolio can buy a small company without breaking the market. Scale, for once, can be a disadvantage.
That idea supports six named publications and a free daily product called Dylan's Diary. The flagship hunts companies valued roughly between $1 billion and $10 billion after what the team considers a temporary setback. Biotech Insider studies drug developers, especially those nearer the end of clinical trials. Breakthrough Wealth moves down into microcaps. Takeover Targets works merger spreads. Hidden Market Profits looks at private companies. America First Fortunes follows reshoring and domestic industry. Different doors, same house: go where attention is thin.
The product is a decision system
A stock newsletter sounds like information. Behind the Markets packages something closer to a recurring decision system: monthly or weekly reports, model-portfolio access, buy and sell alerts, updates, education and a members-only portal. The customer is not merely paying to learn what a biotech company does. The customer wants a name, a price range, a thesis and, eventually, an exit.
That last mile is valuable because it removes work. It is also where education becomes recommendation and the stakes sharpen. A reader can disagree with an essay at no cost. A subscriber acting on an alert can lose money. Behind the Markets acknowledges some of this in useful, specific ways. Breakthrough Wealth says microcaps should make up no more than 5 percent of a stock portfolio. Hidden Market Profits suggests no more than $2,000 in any single private-company recommendation. These are not decorative caveats. They are the operating instructions.
Jovine's biography supplies the authority story. He says he founded New York brokerage and investment bank Lexington Capital Partners in 1996, then launched Tycoon Publishing in 2004 and sold it to Agora in 2011. His personal site says Tycoon reached more than 500,000 investors across 28 countries. Those earlier ventures matter because Behind the Markets is plainly a founder-led media business. Jovine does not simply oversee the product. His experience is the product's wrapper.
“The best investment opportunities are found where Wall Street isn't looking.”
Free insight, then paid specificity
The commercial architecture is tidy. Daily emails, videos and market updates create a free habit. Special reports convert a broad theme - AI infrastructure, precision medicine, Taiwan, takeovers - into curiosity about a particular company. The paid membership resolves the cliffhanger and keeps the subscriber in a portfolio, where alerts and updates can renew the relationship.
Public prices reveal how aggressively that relationship is segmented. The core Behind the Markets page lists tiers at $196 and $399. Several specialist products list $2,997 for one year, $3,997 for two, and $4,997 for access for as long as the publication continues. America First Fortunes lists an annual tier at $5,000 and an open-ended tier at $10,000. Promotional pages may show different offers, which makes the checkout context important.
This is a direct-to-consumer publishing business, not an asset manager. The economics likely favor subscriptions: produce one body of research, sell access repeatedly, and use email to keep acquisition costs under control. The firm also received a reported $100,000 in debt financing in 2021, but it publishes no current revenue or valuation. Its visible footprint - a team listed by LinkedIn in the 11-to-50 range, a steady publishing cadence and multiple portals - looks more like a focused media shop than a sprawling financial institution.
What failed first: the easy story
The most instructive Behind the Markets article is not a winning-stock victory lap. It is Jovine's December 2025 review of Biotech Insider. The headline average return on closed trades that year was 59.48 percent. Then came the denominator: two positions. Eli Lilly was sold for a reported 151 percent gain; Novo Nordisk was exited at roughly a 34 percent loss. The arithmetic was accurate. The sample was tiny.
Jovine wrote that the first nine months had been hard and frustrating, with biotech broadly under pressure. He also argued that a one-year track record could mislead even when technically correct. That admission exposes what fails first in a concentrated research service: not necessarily the thesis, but the smooth narrative. Sectors go cold. Clinical timelines slip. A model portfolio can spend months looking foolish before anyone learns whether patience was discipline or denial.
It also explains what changed Jovine's mind about biotech in the first place. In his own account, a severe health episode led him to genetically tailored treatment and then to questions about the companies behind precision medicine. Personal curiosity became an investment specialty. It is a compelling origin story, but it does not make biotechnology simple. Trials fail, regulators surprise, companies dilute shareholders and scientific promise can outrun commercial reality.
Works when
The subscriber has a diversified portfolio, a long horizon, enough time to verify the thesis and the temperament to size speculative positions modestly.
Breaks when
A persuasive alert replaces due diligence, money needed soon enters illiquid stocks, or a customer confuses a publisher's conviction with a guarantee.
Customer experience is the other stress test. Trustpilot reviews are heavily negative, with repeated allegations concerning frequent upsells, billing, refunds, access and slow support. Reviews are user claims, not audited findings, but the pattern is relevant to any subscription company selling expensive, high-trust products. The site advertises a 30-day money-back guarantee. A buyer should save the offer terms, understand renewal conditions, test portal access immediately and judge support before the refund window closes.
That is not a side issue. In investment publishing, service quality and research credibility share the same account balance. Every unclear charge spends trust that the analyst will need during the next drawdown.
The part worth stealing
For a creator or research founder, Behind the Markets offers a clean playbook. Do not begin with “finance.” Begin with a structural reason the incumbent cannot serve a particular corner well. Turn that reason into a sentence readers can remember. Publish often enough to create a habit. Then divide paid depth by job-to-be-done, not by arbitrary content volume.
- Own one asymmetryLarge funds cannot efficiently pursue every small stock. The brand repeats that constraint until it becomes positioning.
- Build the free ritualDaily commentary and video let readers sample judgment before buying a research service.
- Sell distinct outcomesValue, biotech, microcaps, takeovers and private markets each get a named product with a recognizable use.
- Publish the ugly reviewA small sample and a losing trade teach more about process than another isolated winner.
What cannot be copied cheaply is founder credibility. Jovine has decades of market and publishing experience, a personal narrative suited to the products, and the stamina to appear constantly. A new publisher with no audited history cannot manufacture that with sharper landing-page adjectives. It has to substitute transparent methodology, documented calls, restrained claims and customer service that answers the phone.
Where it fits
Behind the Markets sits between mass financial media and bespoke wealth management. It is narrower and more actionable than a newspaper, cheaper than hiring an analyst, more opinionated than brokerage research and more expensive than most general-interest newsletters. Competitors range from Motley Fool and Seeking Alpha to Stansberry, InvestorPlace, Cabot and a thousand Substacks. The functional alternative is less glamorous: buy a diversified low-cost fund and ignore stock alerts altogether.
For the right customer, the service can function as an idea generator and research shortcut. The wrong customer is someone seeking certainty, needing quick liquidity or tempted to concentrate a portfolio around a vivid story. The useful discipline is to separate idea discovery from order entry. Read the report. Check the filings. Test the valuation. Decide the maximum loss first. Then, perhaps, act.
Behind the Markets has identified a legitimate market gap and built a coherent publishing machine around it. Its strongest product may be the permission it gives ordinary investors to look beyond the obvious. Its biggest danger is the same permission, delivered with enough confidence and urgency that curiosity becomes overcommitment. The edge is not merely finding a stock Wall Street skipped. It is remaining independent enough to skip the stock yourself.